Opus Genetics, Inc.
General ticker "IRD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Opus Genetics, Inc. follows the US Stock Market performance with the rate: 43.3%.
Estimated limits based on current volatility of 3.8%: low 3.11$, high 3.35$
Factors to consider:
- Total employees count: 28 (+55.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Clinical trial failure, Manufacturing risks, Capital raising, Sales infrastructure
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.20$, 3.35$]
- 2026-12-31 to 2027-12-31 estimated range: [0.91$, 2.63$]
Short-term IRD quotes
Long-term IRD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $19.05MM | $10.99MM | $14.20MM |
| Operating Expenses | $29.61MM | $73.07MM | $52.80MM |
| Operating Income | $-10.56MM | $-62.07MM | $-38.60MM |
| Non-Operating Income | $0.59MM | $4.54MM | $-10.99MM |
| Interest Expense | $0.00MM | $0.00MM | $0.13MM |
| R&D Expense | $17.65MM | $26.85MM | $30.81MM |
| Income(Loss) | $-9.97MM | $-57.53MM | $-49.59MM |
| Taxes | $0.01MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-9.99MM | $-57.53MM | $-49.59MM |
| Stockholders Equity | $49.91MM | $6.72MM | $15.35MM |
| Assets | $53.95MM | $36.86MM | $50.24MM |
| Operating Cash Flow | $-1.11MM | $-25.58MM | $-35.25MM |
| Investing Cash Flow | $0.00MM | $1.21MM | $0.00MM |
| Financing Cash Flow | $8.98MM | $4.19MM | $50.02MM |
| Earnings Per Share** | $-0.46 | $-2.15 | $-0.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.